OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a report issued on Thursday. The firm issued a sell rating on the stock.

Separately, Needham & Company LLC restated a “buy” rating and set a $4.25 price objective on shares of OncoCyte in a research report on Wednesday.

OncoCyte Trading Down 6.8 %

NASDAQ OCX opened at $2.61 on Thursday. OncoCyte has a 1-year low of $2.29 and a 1-year high of $4.34. The company has a 50 day moving average of $3.02 and a 200-day moving average of $2.98.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.54). OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. The firm had revenue of $0.12 million for the quarter. During the same period in the prior year, the company posted ($0.57) EPS.

Insider Transactions at OncoCyte

In related news, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was bought at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the acquisition, the insider now owns 6,244,405 shares of the company’s stock, valued at approximately $18,420,994.75. This represents a 26.69 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrea S. James acquired 33,670 shares of OncoCyte stock in a transaction that occurred on Wednesday, October 2nd. The stock was acquired at an average cost of $2.97 per share, for a total transaction of $99,999.90. Following the purchase, the chief financial officer now owns 33,670 shares of the company’s stock, valued at $99,999.90. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.58% of the company’s stock.

Institutional Trading of OncoCyte

A hedge fund recently raised its stake in OncoCyte stock. Geode Capital Management LLC raised its position in shares of OncoCyte Co. (NASDAQ:OCX) by 12.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 103,980 shares of the company’s stock after acquiring an additional 11,289 shares during the quarter. Geode Capital Management LLC owned about 0.62% of OncoCyte worth $296,000 as of its most recent SEC filing. Institutional investors own 55.35% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.